Literature DB >> 24308859

Successful treatment of macular retinoblastoma with superselective ophthalmic artery infusion of melphalan.

Theodora Hadjistilianou, Gianni Coriolani, Sandra Bracco, Paola Gennari, Mauro Caini, Alfonso Cerase, Daniela Galimberti, Sonia De Francesco, Mariacarla De Luca, Domenico Mastrangelo.   

Abstract

PURPOSE: To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible.
METHODS: Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment.
RESULTS: The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case.
CONCLUSIONS: SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy. Copyright 2014, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308859     DOI: 10.3928/01913913-20131203-01

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  2 in total

1.  Intra-Arterial Chemotherapy as Primary Therapy for Retinoblastoma in Infants Less than 3 Months of Age: A Series of 10 Case-Studies.

Authors:  Miaojuan Chen; Junyang Zhao; Jiejun Xia; Zhenyin Liu; Hua Jiang; Gang Shen; Haibo Li; Yizhou Jiang; Jing Zhang
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

2.  Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC.

Authors:  David H Abramson; Armida W M Fabius; Reda Issa; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Y Pierre Gobin
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.